SYRE
Spyre Therapeutics, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -20.0% ·
share flow -21.7% ·
net new positions -20.0%
— formula
Broad distribution — falling shares and fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 99 | +22 | 55.44M | $4.93B | +25 | −3 |
| Q1 2026 | 80 | +10 | 41.69M | $2.10B | +12 | −2 |
| Q4 2025 | 69 | +2 | 41.90M | $1.37B | +2 | — |
| Q3 2025 | 13 | -1 | 23.21M | $388.94M | +1 | −2 |
| Q2 2025 | 11 | 0 | 22.40M | $335.38M | +2 | −2 |
| Q1 2025 | 8 | -2 | 6.01M | $96.96M | — | −2 |
| Q4 2024 | 10 | +1 | 7.67M | $178.64M | +2 | −1 |
| Q3 2024 | 8 | 0 | 4.78M | $140.58M | +1 | −1 |
| Q2 2024 | 8 | — | 3.96M | $93.00M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | State Street Global Advisors ✦ (passive) | 1.70M | +1.0% | $27.38M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 2 | Wellington Management ✦ | 1.59M | -0.7% | $25.71M | 0.0% | ▼ Trim | 4 | SEC ↗ ×5 |
| 3 | Geode Capital Management ✦ (passive) | 1.06M | +9.7% | $17.10M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 4 | Adage Capital Partners ✦ | 803.20K | -22.0% | $12.96M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 5 | Capital World Investors ✦ | 350.77K | -7.3% | $5.66M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 6 | T. Rowe Price ✦ | 248.54K | -50.9% | $4.01M | 0.0% | ▼ Trim | 4 | SEC ↗ ×2 |
| 7 | Citadel Advisors ✦ | 130.88K | -87.9% | $2.11M | 0.0% | ▼ Trim | 4 | SEC ↗ ×2 |
| 8 | Soros Fund Management ✦ | 125.00K | -50.0% | $2.02M | 0.1% | ▼ Trim | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Millennium Management | $3.91M | was 0.0% |
| Two Sigma Investments | $224,373 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 197 holders, 82.12M shares, $4.06B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 229 sh · $21,428
Officer · 1.50K sh · $135,405
Officer · 3.07K sh · $285,449
Officer · 600 sh · $53,442
Officer · 2.10K sh · $193,032
Officer · 17.50K sh · $1.57M
Officer · 18.23K sh · $1.63M
Officer · 400 sh · $36,000
Officer · 16.55K sh · $1.44M
Officer · 900 sh · $77,625
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology
9.2% of class · View original SEC filing ↗
9.2% of class · View original SEC filing ↗